Media Lab S.p.A (MLLAB) Fair Value & Analysis
Healthcare · FR · Market cap €7.6M
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 24 days ago
Fair value updated Jul 17, 2026, revised from €3.42 to €1.40 (−59.1%) since Jun 24, 2026.
A solid business, but screening 56% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (€1.78). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (€0.9500 to €1.78) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range €0.4985 – €6.40 · fair‑value band €0.9500 – €1.78 · the €3.20 price screens above the €1.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Media Lab S.p.A (MLLAB) currently trades at €3.20, while our model-based Fair Value estimate is €1.40, implying the stock looks roughly 56.3% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Media Lab S.p.A generated revenue of €1.8M at a net margin of 23.2%. It earns a return on equity of 35.1%. The stock trades on a trailing P/E of 18.8. Fundamentals as of Jul 17, 2026
Our scenario range runs from €0.9500 (bear case) to €1.78 (bull case); at €3.20, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 68% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -56%, MLLAB screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Dividend Discount (€1.71) versus Asset-Based (€0.3200). Highest evidence: Growth DCF (80).
Notify me when MLLAB reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Media Lab S.p.A. specializes in the development of software dedicated to the dental sector. It offers Implant 3D, an implant planning software and surgical guide creation that allows the user to perform 3D implant simulation directly on PC; tools and accessories for implantology and guided surgery; and training, and assistance services.
Full company description
Media Lab S.p.A. specializes in the development of software dedicated to the dental sector. It offers Implant 3D, an implant planning software and surgical guide creation that allows the user to perform 3D implant simulation directly on PC; tools and accessories for implantology and guided surgery; and training, and assistance services. The company was founded in 1994 and is headquartered in Follo, Italy.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Media Lab S.p.A reported revenue of €1.4M in FY2025 versus €1.2M in FY2021, a compound +4.2%/yr. Reported net income was €154K in FY2025, compounding +12.9%/yr from FY2021.
of which total revenue +11.8 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
MLLAB screens 56% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare Media Lab S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Media Lab S.p.A (MLLAB) overvalued or undervalued?
What is the fair value of MLLAB?
What is the quality score of MLLAB?
What is the revenue of Media Lab S.p.A (MLLAB)?
What is the net profit margin of MLLAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Media Lab S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.